Princeton, New Jersey15 days ago
D., Kardigan’s co-founders have reunited after leading MyoKardia to discover and develop mavacamten, the first cardiac myosin inhibitor, resulting in an acquisition by Bristol Myers Squibb in 2020.
We have a cutting-edge discovery and translational research platform, a pipeline of late-stage candidates, and an industry-leading team that is driven to improve the lives of patients.
At Kardigan, we are motivated by our values which guide how we work, interact, and achieve our goals.
The Executive Director, Development Business Operations establishes and leads development business operations across the clinical portfolio, including budgets and forecasting, metrics and analytics, resource planning, clinical procurement, and site contracts and budgets.